RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer
That would be nice but a lot of if's but let's first get a trial approved before we get ahead of ourselves as we have done this before getting our hopes up. Big thing out of this is that the company has never run a quick trial and if it does not get started until sometime in 2025 depending upon enrollment and then waiting for results from let's say the first 100 patients to show some kind of efficacy and remember that pela seems to kick in a few months later for the immunotherapy and that thiese patients are 3rd line patients with compromised immune systems after all of the treatments then when can we really expect our first set of results. Hopefully before the patents run out.
IF it all works out then we have no limits IMO to where the company can be or the valuation but we have to be real in all of this and look at how long it will really take for things to unfold. First we need to have trial peramiters and protocols and treatment set out by the company and then sent to the fda for approval. And then they have to have all the treatment centers set up and get their approvals.
ON top of all of that the company will either need to raise money or get a partnership or BO. We will be lucky if the trial even starts in 2025 IMO of course.Let's see what the mbc OS readout is and how if any that it affects the sp or negotiations as the company has basically stated that they need more information to take to BP to help with negotiations.
Also would be nice since they say that they can extend the patents that they would just do so and also if they could clear up any confusion in regards to the DEC 2023 options that were never declared on sedi which is a securities requirement. So are they in a Blackout or not, that remains to be seen.
Some of the above IMO of course